24/7 Wall St. » CGRB

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

247wallst — Wed, 27 May 2009 18:34:32 +0000

We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend. This is broken down in drug and biotech companies with share values, ranges, and recent developments for the following drug and biotech companies: Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).

The full presentation can be seen at BioHealthInvestor.com.

JON C. OGG
May 27, 2009

Posted in Biotech, Drug companies, FDA, Medical, Pharmaceuticals Tagged: ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CELG, CGRB, CLDX, CTIC, EXEL, GHDX, GSK, IMGN, LLY, MDVN, MEDX, MITI, OGXI, OSIP, PFE, PPHM, ROSG, SNTA, TRBN, ZGEN, ZIOP

Previewing 2009 ASCO Abstracts (ABII, ALTH, ARQL, CLDX, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, OGXI, OSIP, PPHM, PFE, SNTA, ZIOP)

247wallst — Thu, 14 May 2009 21:56:52 +0000

We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009. At BioHealthInvestor.com we compiled a brief summary for companies such as Abraxis BioScience, Inc. (NASDAQ:ABII), Allos Therapeutics, Inc. (NASDAQ: ALTH), Arqule Inc. (NASDAQ: ARQL), Celldex Therapeutics (NASDAQ: CLDX), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Synta Pharmaceuticals (NASDAQ: SNTA), and ZIOPHARM Oncology (NASDAQ: ZIOP).

You can see that full pre-report here at BiohealthInvestor.com. As always be advised that there may be new sets of data released between now and the actual meeting from May 29 to June 2, 2009 in Orlando, Florida.

Posted in Biotech, Drug companies, Medical, Pharmaceuticals Tagged: ABII, ALTH, ARQL, CGRB, CLDX, CTIC, EXEL, GHDX, GSK, IMGN, LLY, MDVN, MEDX, OGXI, OSIP, PFE, PPHM, SNTA, ZIOP

Biotech Business Daily (CGRB, DSCO, EPIX, GSK, PSTI, VNDA)

247wallst — Mon, 05 May 2008 13:51:42 +0000

Cougar Biotechnology, Inc. (NASDAQ: CGRB) is up over 5% in afternoon trading on the announcement that they will present a company update and clinical trial update at the Leerink Swann Cancer Roundtable Conference. Shares up $0.88 to $21.43. The 52-week range is $17.00 to $34.00.

Discovery Laboratories (NASDAQ: DSCO) shares are on roller coaster ride as they anticipate the await approval for Surfaxin, a preventative medicine for respiratory distress syndrome in premature infants. Last Friday, the stock dropped 50% after the FDA wrote an Approvable Letter to Discovery requesting more information. Today it is up 33% after Discovery announced that additional clinical trials will not be necessary. Shares are trading at $1.87 on extremely high relative trading volume. The 52-week range is $1.29 to $3.75.

EPIX Pharmaceuticals (NASDAQ: EPIX) announced the mid-stage human clinical trial launch of Alzheimer’s treatment, PRX-03140, making it eligible for a milestone payment of $7.5 million from GlaxoSmithKline (NYSE: GSK). Shares are up over 8% to $1.80. The 52-week range is $1.28 to $6.70.

Pluristem Therapeutics, Inc. (NASDAQ: PSTI) shares are down over 13% today on no new relevant news. Shares are down $0.63 to $3.96. The 52-week range is $1.52 to $28.00.

Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) shares are up almost 40% today after reporting narrower first quarter losses last Thursday, beating expectations. Also, Caris initiated coverage on the company with a “Buy” rating and a $22.00 price target, specifically citing the expectation that schizophrenia treatment Fanapta, will gain regulatory approval in July. Today, shares are up $1.68 to $5.89. The 52-week range is $2.70 to $22.49.

Rachel Lopez
May 5, 2008

Biotech Monday (CRIS, CGRB, EXEL, MNKD, PDLI, SQNM, TCM)

247wallst — Mon, 10 Mar 2008 14:25:45 +0000

Curis Inc. (NASDAQ: CRIS) shares down 18% after development partner Wyeth terminated their contract that focused on cancer treatment developments. Shares are down $0.29 to $1.14. The 52 week range is $0.86 to $2.35.

Cougar Biotechnology, Inc. (NASDAQ: CGRB) down 23% to $17.75.

Exelixis (NASDAQ: EXEL) hit a new 5 year low this morning. Its down 7% to $5.38 on a 52 week low of $5.67 to $12.77. No special reason for the downturn aside from a market wide lack of interest in developmental-stage drugs.

MannKind Corp. (NASDAQ: MNKD) downgrades and fears of ending inhaled insulin development lead to a new all-time low. Shares are down 18% at $4.52 in mid-day trading. The 52 week range is $5.25 to $15.99.

PDL BioPharma (NASDAQ: PDLI) fell another 8% after the recent drops after it canceled its sale last week. Its shares hit lows of $10.12, another 52-week low.

Sequenom Inc. (NASDAQ: SQNM) down 17% on no new news. Shares are trading at $5.47 with a 52 week range of $2.93 to $11.63.

Tongjitang Chinese Medicines Co. (NYSE: TCM) shares are up over 33% to $8.83 in mid-day trading on news that the CEO and another board director submitted a proposal to acquire all outstanding shares and take the company private. The 52 week range is $6.57 to $12.88.

Rachel Lopez
March 10, 2008